Meisha Sampson InspectorProfile

This FDA InspectorProfile is a report of relevant audit-related information on Meisha Sampson, a U.S. Food & Drug Administration investigator who primarily conducts inspections in the area of Human Drugs.

Product Description

This InspectorProfile report is updated through Jan 2018 and lists Meisha Sampson's inspections in 15 countries: United States, France, Italy, Germany, China, United Kingdom, India, Sweden, Israel, Australia, Dominican Republic (the), Spain, Netherlands, Guyana, and Romania.

FDA audits are stressful. Whether you are issued a 483 depends largely on your compliance with GxP and predicate rules; but it can also depend on the Agency's current focus and the tendencies of your specific investigator(s). FDAzilla has curated Meisha Sampson's inspection information so that you can mitigate investigator-related risks.

Example Report

Below is an example of what a FDAzilla InspectorProfile report contains; This is not the actual data for Meisha Sampson.

Product details

• Meisha Sampson's metrics:
  • 483 issue rate, total inspections, total 483s
  • Most common citations (based on CFR), CFR description, and citation frequency
  • Total inspections, total 483s
  • Longest / shortest inspection in duration - all time, last year
  • Total warning letters
• Inspection details for each inspection (since 2000) Meisha Sampson has conducted including:
  • Company, site inspected, duration of inspection
  • Co-inspectors Lane Christensen, Doan Nguyen, Cassandra Abellard, Charles Zhou, David Anderson, year of last co-inspection, number of co-inspections
  • If a 483 issued, and whether or not it resulted in a warning letter.

Note: The EIR and 483 documents are sold separately.